About Us
WELCOME TO FABISMAN INVESTMENT
We are a family-owned fund house with a keen eye on life sciences and other investment prospects.
Our investment approach centres around direct primary and secondary transactions that align with our objectives. As secondary investors, we’re adaptable, offering flexible liquidity solutions for fellow investors or companies looking to divest part or all of their investment assets, or seeking extra capital and resources to enhance investment results. We’re also open to injecting fresh capital, joining follow-on financings, and contributing to key programs with value-adding support.
OUR TEAM
The core team at Fabisman Investment consists of two key persons, alongside other stakeholders.
Dr. Feisal Suleiman S Abukscem (PhD)
Dr. Feisal Suleiman S. Abukscem is a self-made entrepreneur with over 40 years of diverse business experience, particularly in healthcare and pharmaceuticals. His extensive background spans multiple industries, showcasing his versatility and expertise in building successful ventures.
Mr Gautam K Chakraborty
Mr. Gautam K. Chakraborty is a finance professional with over 40 years of experience in operational and business finance. His career spans several geographies, primarily with a large multinational pharmaceutical company, where he has demonstrated his expertise and leadership in the financial sector.
OUR VISION
Our vision is to achieve impeccable quality by delivering exceptional management performance and premium services to our investors. An integral part of this vision is delivering superior returns to our shareholders, aligned with our pre-defined risk profile and alignment with innovative corporations, whilst still upholding high ethical standards and contributing to societal development through integrity and fair business practices.
We seek to build lasting parnerships underpinned by trust and credibility.
We do this via:
OUR REACH
Global Platform
OUR EXPERTISE
Deep Industry Knowledge
OUR DIVSESE INCLUSIVE TEAM
Better Insights
Investment History
2012
January 1st
Luxury residential tower in Dubai Marina.
2019
June 28th
Investment in Fund
October 8th
A Swiss clinical-stage biotechnology company with an encapsulated cellular cancer immunotherapy.
2020
July 14th
Medical curved implants for curved bones within the body.
September 15th
Orthopaedic surgery instrumentation.
September 25th
Investment in Fund
October 28th
A neuromodulation company based in the USA.
2021
January 11th
A next-generation asset management company.
January 15th
Investment in Fund
January 18th
Investment in Series BB Prefered Stock
April 29th
Orthopaedic surgery instrumentation.
June 1st
Second tranche investment.
June 13th
Investment in shares.
June 21st
Participation in the second closing of Series B-1 shares.
September 27th
New capital contribution.
2022
January 16th
Participation in the milestone closing of Series B-1 shares.
February 1st
Participating in NEMO V with Garuda Therapeutics and Magnolia Medical Technologies.
February 28th
A neuromodulation company based in the USA.
April 6th
Participating in NEMO V with Garuda Therapeutics and Magnolia Medical Technologies.
September 28th
Investment in Capital Call 3
December 11th
A neuromodulation company based in the USA.
2023
January 15th
Investment in Capital Call 4
February 9th
Investment in Convertible Loan
March 15th
Investment in Capital Call Cash Less
March 23rd
Investment in Capital Call 5
May 22nd
Investment in Convertible Loan
July 12th
Investment in Series C Preferred Stock
July 18th
Investment in Capital Call 6
September 11th
Investment in shares.
November 21st
Investment in Capital Call 7
2024
January 28th
Investment in C1 Preffered Stock
January 28th
Investment in C2 Shares
May 3rd
Investment in shares.
May 3rd
Investment of Convertible Loan
June 20th
Investment in Capital Call 8
November 14th
Investment in C1 Shares
2025
April 2nd
Investment in Capital Call 9
June 30th
Invetment in Series D Preferred Shares
September 2nd
Investment in shares.
GET IN TOUCH
We create sustainable growth for investors around the world with our innovative investments in the life sciences and real estate sectors. If you wish to learn, we’d love to hear from you.